Harms From Haloperidol for Symptom Management in Palliative Care: a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies

Hiromichi Matsuoka; Meera Agar; Zac Vandersman; Philip Good; Belinda Fazekas; Linda Brown; Janet Hardy; Jennifer Weil; David Christopher Currow

doi:10.1016/j.jpainsymman.2019.05.004

Harms From Haloperidol for Symptom Management in Palliative Care: a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies

Hiromichi Matsuoka, Meera Agar, Zac Vandersman, Philip Good, Belinda Fazekas, Linda Brown, Janet Hardy, Jennifer Weil, David Christopher Currow

Research output: Contribution to journal › Letter › peer-review

2 Citations (Scopus)

Abstract

Introduction
Symptom control for people with cancer improves quality of life. Haloperidol is a key drug in palliative care and is frequently used for the treatment of delirium, nausea, and vomiting.1 Haloperidol, a butyrophenone, is a more potent D2 receptor antagonist than other antiemetics, such as prochlorperazine, olanzapine, or chlorpromazine.

Original language	English
Pages (from-to)	e6-e8
Number of pages	3
Journal	Journal of Pain and Symptom Management
Volume	58
Issue number	3
DOIs	https://doi.org/10.1016/j.jpainsymman.2019.05.004
Publication status	Published - 3 Sep 2019
Externally published	Yes

Keywords

cancer
haloperidol
palliative care

Access to Document

10.1016/j.jpainsymman.2019.05.004Licence: In Copyright

Cite this

Matsuoka, H., Agar, M., Vandersman, Z., Good, P., Fazekas, B., Brown, L., Hardy, J., Weil, J., & Currow, D. C. (2019). Harms From Haloperidol for Symptom Management in Palliative Care: a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies. Journal of Pain and Symptom Management, 58(3), e6-e8. https://doi.org/10.1016/j.jpainsymman.2019.05.004

@article{12d719e09c4040cdb9be87bbb8b4e564,

title = "Harms From Haloperidol for Symptom Management in Palliative Care: a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies",

abstract = "IntroductionSymptom control for people with cancer improves quality of life. Haloperidol is a key drug in palliative care and is frequently used for the treatment of delirium, nausea, and vomiting.1 Haloperidol, a butyrophenone, is a more potent D2 receptor antagonist than other antiemetics, such as prochlorperazine, olanzapine, or chlorpromazine.",

keywords = "cancer, haloperidol, palliative care",

author = "Hiromichi Matsuoka and Meera Agar and Zac Vandersman and Philip Good and Belinda Fazekas and Linda Brown and Janet Hardy and Jennifer Weil and Currow, {David Christopher}",

year = "2019",

month = sep,

day = "3",

doi = "10.1016/j.jpainsymman.2019.05.004",

language = "English",

volume = "58",

pages = "e6--e8",

journal = "Journal of Pain and Symptom Management",

issn = "0885-3924",

publisher = "Elsevier",

number = "3",

}

Matsuoka, H, Agar, M, Vandersman, Z, Good, P, Fazekas, B, Brown, L, Hardy, J, Weil, J & Currow, DC 2019, 'Harms From Haloperidol for Symptom Management in Palliative Care: a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies', Journal of Pain and Symptom Management, vol. 58, no. 3, pp. e6-e8. https://doi.org/10.1016/j.jpainsymman.2019.05.004

Harms From Haloperidol for Symptom Management in Palliative Care : a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies. / Matsuoka, Hiromichi; Agar, Meera; Vandersman, Zac et al.

In: Journal of Pain and Symptom Management, Vol. 58, No. 3, 03.09.2019, p. e6-e8.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Harms From Haloperidol for Symptom Management in Palliative Care

T2 - a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies

AU - Matsuoka, Hiromichi

AU - Agar, Meera

AU - Vandersman, Zac

AU - Good, Philip

AU - Fazekas, Belinda

AU - Brown, Linda

AU - Hardy, Janet

AU - Weil, Jennifer

AU - Currow, David Christopher

PY - 2019/9/3

Y1 - 2019/9/3

N2 - IntroductionSymptom control for people with cancer improves quality of life. Haloperidol is a key drug in palliative care and is frequently used for the treatment of delirium, nausea, and vomiting.1 Haloperidol, a butyrophenone, is a more potent D2 receptor antagonist than other antiemetics, such as prochlorperazine, olanzapine, or chlorpromazine.

AB - IntroductionSymptom control for people with cancer improves quality of life. Haloperidol is a key drug in palliative care and is frequently used for the treatment of delirium, nausea, and vomiting.1 Haloperidol, a butyrophenone, is a more potent D2 receptor antagonist than other antiemetics, such as prochlorperazine, olanzapine, or chlorpromazine.

KW - cancer

KW - haloperidol

KW - palliative care

UR - http://www.scopus.com/inward/record.url?scp=85070939044&partnerID=8YFLogxK

U2 - 10.1016/j.jpainsymman.2019.05.004

DO - 10.1016/j.jpainsymman.2019.05.004

M3 - Letter

C2 - 31121249

AN - SCOPUS:85070939044

VL - 58

SP - e6-e8

JO - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

SN - 0885-3924

IS - 3

ER -

Harms From Haloperidol for Symptom Management in Palliative Care: a Post Hoc Pooled Analysis of Three Randomized Controlled Studies and Two Consecutive Cohort Studies

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this